- Sientra ( NASDAQ: SIEN ) on Wednesday said the U.S. FDA had approved its breast implant product for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.
- SIEN said the product, Low Plus Profile Projection Breast Implant, would be commercially available for certified and eligible plastic surgeons in the U.S. in late July.
- SIEN said it would be first implant maker in the U.S. to offer 80cc and 110cc gel implants, with the two new sizes bringing more options to surgeons and their patients.
- SIEN stock slightly lower in volatile early trading.
For further details see:
FDA approves Sientra’s breast implant product for breast augmentation, reconstruction